[go: up one dir, main page]

DE60110106D1 - Verfahren zur herstellung von pankreasenzym enthaltende mikrosphären mit hoher stabilität - Google Patents

Verfahren zur herstellung von pankreasenzym enthaltende mikrosphären mit hoher stabilität

Info

Publication number
DE60110106D1
DE60110106D1 DE60110106T DE60110106T DE60110106D1 DE 60110106 D1 DE60110106 D1 DE 60110106D1 DE 60110106 T DE60110106 T DE 60110106T DE 60110106 T DE60110106 T DE 60110106T DE 60110106 D1 DE60110106 D1 DE 60110106D1
Authority
DE
Germany
Prior art keywords
producing
pancreasenzym
high stability
containing microspheres
microspheres
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60110106T
Other languages
English (en)
Other versions
DE60110106T2 (de
Inventor
Mario Maio
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aptalis Pharma SRL
Original Assignee
Eurand International SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11446110&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE60110106(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eurand International SpA filed Critical Eurand International SpA
Publication of DE60110106D1 publication Critical patent/DE60110106D1/de
Application granted granted Critical
Publication of DE60110106T2 publication Critical patent/DE60110106T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/54—Mixtures of enzymes or proenzymes covered by more than a single one of groups A61K38/44 - A61K38/46 or A61K38/51 - A61K38/53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C12N11/082—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60110106T 2000-11-15 2001-11-13 Verfahren zur herstellung von pankreasenzym enthaltende mikrosphären mit hoher stabilität Expired - Lifetime DE60110106T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT2000MI002456A IT1319655B1 (it) 2000-11-15 2000-11-15 Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
ITMI20002456 2000-11-15
PCT/EP2001/013115 WO2002040045A2 (en) 2000-11-15 2001-11-13 Microspheres of pancreatic enzymes with high stability

Publications (2)

Publication Number Publication Date
DE60110106D1 true DE60110106D1 (de) 2005-05-19
DE60110106T2 DE60110106T2 (de) 2006-03-02

Family

ID=11446110

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60110106T Expired - Lifetime DE60110106T2 (de) 2000-11-15 2001-11-13 Verfahren zur herstellung von pankreasenzym enthaltende mikrosphären mit hoher stabilität

Country Status (11)

Country Link
US (2) US9259393B2 (de)
EP (1) EP1335706B1 (de)
JP (1) JP4555981B2 (de)
KR (1) KR20030060105A (de)
AT (1) ATE292959T1 (de)
AU (1) AU2002224843A1 (de)
CA (1) CA2428837A1 (de)
DE (1) DE60110106T2 (de)
ES (1) ES2240559T3 (de)
IT (1) IT1319655B1 (de)
WO (1) WO2002040045A2 (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) * 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
US8100844B2 (en) * 2002-04-25 2012-01-24 Ultraflex Systems, Inc. Ambulating ankle and knee joints with bidirectional dampening and assistance using elastomeric restraint
JP5032300B2 (ja) * 2004-03-22 2012-09-26 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング 界面活性剤を含有している、リパーゼを含有する生成物の、とりわけパンクレアチンの経口医薬組成物
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
AU2006274835B2 (en) * 2005-07-29 2012-05-24 Abbott Laboratories Gmbh Processes for the manufacture of sterilized pancreatin powder
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
DE602006012346D1 (de) * 2005-08-15 2010-04-01 Solvay Pharm Gmbh Pharmazeutische zusammensetzungen mit kontrollierter freisetzung für säurelabile arzneimittel
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
DK1931316T4 (en) * 2005-08-15 2017-05-15 Abbott Laboratories Gmbh Controlled-release pharmaceutical compositions for use in acid-labile drugs
JP5284092B2 (ja) * 2005-08-15 2013-09-11 アボット ラボラトリーズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 腸溶コーティングに適したパンクレアチンマイクロペレットコア
CN101242812B (zh) * 2005-08-15 2012-12-26 雅培产品有限公司 适合肠溶包衣的胰酶微丸芯
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
US10072256B2 (en) * 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
TWI421090B (zh) 2007-02-20 2014-01-01 Aptalis Pharma Ltd 穩定之消化酵素組合物
RU2445952C2 (ru) * 2007-02-20 2012-03-27 Юранд Фармасьютикалз Лимитед Стабильные композиции пищеварительных ферментов
US20090130063A1 (en) * 2007-11-15 2009-05-21 Solvay Pharmaceuticals Gmbh Process for separating and determining the viral load in a pancreatin sample
US10087493B2 (en) 2008-03-07 2018-10-02 Aptalis Pharma Canada Ulc Method for detecting infectious parvovirus in pharmaceutical preparations
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US20090324730A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
US9320780B2 (en) * 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
PL2318035T3 (pl) * 2008-07-01 2019-10-31 Curemark Llc Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego
US10776453B2 (en) * 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
EP2373693A4 (de) 2009-01-06 2012-04-25 Curelon Llc Zusammensetzungen und verfahren zur behandlung bzw. prävention von mundinfektionen durch e.coli
CN102300989B (zh) 2009-01-06 2015-12-09 柯尔朗恩有限责任公司 用于治疗或预防金黄色葡萄球菌感染以及用于根除或减少表面上金黄色葡萄球菌的组合物和方法
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
WO2011090725A2 (en) * 2009-12-29 2011-07-28 Impax Laboratories, Inc. Gastroretentive solid oral dosage forms with swellable hydrophilic polymer
AU2011248293A1 (en) * 2010-05-03 2012-11-15 Eurand Pharmaceuticals Limited Micropellet compositions comprising pancreatin containing digestive enzyme mixtures
PT2621476E (pt) 2010-10-01 2014-10-16 Aptalis Pharma Ltd Formulações de pancrelipase de baixa potência com revestimento entérico
US20140147500A1 (en) * 2010-11-19 2014-05-29 Joan M. Fallon Preparation and Use of Combination Enzyme and Gastrointestinal Modulator Delivery Systems
JP5976100B2 (ja) 2011-04-21 2016-08-23 キュアマーク リミテッド ライアビリティ カンパニー 神経精神障害の処置のための化合物
RU2016119726A (ru) 2011-08-08 2018-11-02 Апталис Фарма Лтд. Способ проведения теста на растворение твердых композиций, содержащих пищеварительные ферменты
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
EP2903603A4 (de) 2012-09-27 2016-08-10 Cynvenio Biosystems Inc Stimulusempfindliche mikropartikel und verfahren zur verwendung
WO2015020943A2 (en) 2013-08-09 2015-02-12 Aptalis Pharma Ltd. Digestive enzyme composition suitable for enteral administration
JP2017519490A (ja) 2014-06-19 2017-07-20 アプタリス ファルマ リミテッド 膵臓抽出物からのウイルス汚染の除去方法
CN107073084B (zh) 2014-11-05 2022-03-25 雅培制药股份有限公司 用于生产具有改善的安全特性的具有脂肪酶活性的组合物和适用于药物用途的组合物的方法
US12226464B2 (en) 2017-04-10 2025-02-18 Curemark, Llc Compositions for treating addiction
CN110075279A (zh) * 2019-04-25 2019-08-02 淮安麦德森制药有限公司 胰酶微球及其生产方法
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
CN113046233B (zh) * 2021-03-15 2022-07-15 中国科学院过程工程研究所 一种微球-膜集成酶反应器及其制备方法和应用
US12350641B2 (en) * 2021-07-16 2025-07-08 Clearh2O, Inc. Methods of high throughput hydrocolloid bead production and apparatuses thereof

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1342409A (en) 1970-07-23 1974-01-03 Ciba Geigy Ag Flowable pancreatin preparation of low microorgan ism content and a process for its manufacture
GB1509866A (en) 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
US4237229A (en) 1975-06-10 1980-12-02 W. R. Grace & Co. Immobilization of biological material with polyurethane polymers
GB1590432A (en) 1976-07-07 1981-06-03 Novo Industri As Process for the production of an enzyme granulate and the enzyme granuate thus produced
JPS5535031A (en) 1978-09-04 1980-03-11 Shin Etsu Chem Co Ltd Enteric coating composition
DE2923279C2 (de) 1979-06-08 1987-07-09 Kali-Chemie Pharma Gmbh, 3000 Hannover Verfahren zur Herstellung von Pankreatin-Pellets und diese enthaltende Arzneimittel
JPS5855125B2 (ja) 1980-03-10 1983-12-08 信越化学工業株式会社 固形薬剤用腸溶性コ−テイング剤組成物
JPS5885159A (ja) 1981-11-17 1983-05-21 Furointo Sangyo Kk 溶出試験装置
EP0115023B1 (de) 1982-12-30 1988-07-27 Nordmark Arzneimittel GmbH Verfahren zur Gewinnung von Pankreatin
US4447412A (en) 1983-02-01 1984-05-08 Bilton Gerald L Enzyme-containing digestive aid compostions
US4704295A (en) 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
DE3445301A1 (de) 1984-12-12 1986-06-12 Hoechst Ag, 6230 Frankfurt Pankreasenzympraeparate und verfahren zu deren herstellung
JP2521504B2 (ja) * 1985-12-27 1996-08-07 昭和電工株式会社 酵素の造粒法
US4849227A (en) 1986-03-21 1989-07-18 Eurasiam Laboratories, Inc. Pharmaceutical compositions
AU608756B2 (en) 1986-03-21 1991-04-18 Eurasiam Laboratories, Inc. Compositions for the oral administration of biologically active materials
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
IT1205716B (it) 1987-01-21 1989-03-31 Samil Spa Procedimento per la preparazione di microsfere gastroresistenti ed enterosolubili di enzima digestivo e preparato faramceutico a microsfere cosi' prodotto
DK435687D0 (da) 1987-08-21 1987-08-21 Novo Industri As Enzymholdigt granulat og fremgangsmaade til fremstilling deraf
JPH0757312B2 (ja) * 1987-12-11 1995-06-21 昭和電工株式会社 造粒用バインダー
JP2598674B2 (ja) * 1988-05-06 1997-04-09 昭和電工株式会社 酵素含有水溶性マイクロカプセルの製造法
US5733763A (en) 1988-08-19 1998-03-31 Novo Nordisk A/S Enzyme granulate formed of an enzyme-containing core and an enzyme-containing shell
DK78189D0 (da) 1989-02-20 1989-02-20 Novo Industri As Enzymholdigt granulat og fremgangsmaade til fremstilling deraf
DK78089D0 (da) 1989-02-20 1989-02-20 Novo Industri As Detergentholdigt granulat og fremgangsmaade til fremstilling deraf
DK306289D0 (da) 1989-06-21 1989-06-21 Novo Nordisk As Detergentadditiv i granulatform
CA2030581C (en) 1989-11-24 2000-06-27 Gunther Atzl Pancreatin preparations
IT1246350B (it) 1990-07-11 1994-11-17 Eurand Int Metodo per ottenere una rapida sospensione in acqua di farmaci insolubili
JP3055799B2 (ja) * 1990-11-21 2000-06-26 塩野義製薬株式会社 パンクレアチン含有組成物
RU2096452C1 (ru) * 1990-12-31 1997-11-20 Пайонир Хай-Бред Интернэшнл, Инк. Способ приготовления микрокапсул из бактерий в жирной кислоте и микрокапсула, содержащая лиофилизированную бактериальную культуру
JPH0790565B2 (ja) 1991-08-06 1995-10-04 株式会社日本製鋼所 樹脂成形プレスのスライド制御方法及びその装置
US5225202A (en) 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
WO1993007859A1 (en) 1991-10-23 1993-04-29 Warner-Lambert Company Novel pharmaceutical pellets and process for their production
SE9200858L (sv) 1992-03-20 1993-09-21 Kabi Pharmacia Ab Metod för framställning av pellets med fördröjd frisättning
US5616483A (en) 1992-06-11 1997-04-01 Aktiebolaget Astra Genomic DNA sequences encoding human BSSL/CEL
US5460812A (en) 1992-06-22 1995-10-24 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5578304A (en) 1992-06-22 1996-11-26 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
US5260074A (en) 1992-06-22 1993-11-09 Digestive Care Inc. Compositions of digestive enzymes and salts of bile acids and process for preparation thereof
DE4227385A1 (de) * 1992-08-19 1994-02-24 Kali Chemie Pharma Gmbh Pankreatinmikropellets
JP3264027B2 (ja) 1993-02-24 2002-03-11 ソニー株式会社 放電セル及びその製造方法
JP2865548B2 (ja) * 1994-03-08 1999-03-08 澁谷油脂株式会社 流動性洗浄用粉粒体およびその製造法
US5955448A (en) 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
DE4422433A1 (de) 1994-06-28 1996-01-04 Cognis Bio Umwelt Mehrenzymgranulat
ES2178077T3 (es) 1994-08-05 2002-12-16 Smithkline Beecham Plc Sustancias farmaceuticas contenidas en recipientes y metodo de desecarlas.
US5733575A (en) 1994-10-07 1998-03-31 Bpsi Holdings, Inc. Enteric film coating compositions, method of coating therewith, and coated forms
WO1996038170A1 (en) 1995-05-31 1996-12-05 Medzyme N.V. Composition to improve digestibility and utilisation of nutrients
US6057139A (en) 1995-06-29 2000-05-02 Mcneil-Ppc, Inc. Preblend of microcrystalline cellulose and lactase for making tablets
JP3510387B2 (ja) * 1995-06-30 2004-03-29 ライオン株式会社 漂白活性化剤造粒物の製造方法、該漂白活性化剤造粒物を含有する漂白剤又は洗剤の製造方法
US5665428A (en) * 1995-10-25 1997-09-09 Macromed, Inc. Preparation of peptide containing biodegradable microspheres by melt process
US5750104A (en) 1996-05-29 1998-05-12 Digestive Care Inc. High buffer-containing enteric coating digestive enzyme bile acid compositions and method of treating digestive disorders therewith
DE19622131A1 (de) 1996-06-01 1997-12-04 Solvay Enzymes Gmbh & Co Kg Neue Enzymgranulate
AU729814B2 (en) 1996-06-04 2001-02-08 Delphian Technology Inc. Improvements in detection systems and methods for predicting the dissolution curve of a drug from a pharmaceutical dosage form
JPH1023888A (ja) 1996-07-10 1998-01-27 Kao Corp 酵素造粒物の製造方法
US8828432B2 (en) 1996-10-28 2014-09-09 General Mills, Inc. Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
GB9623205D0 (en) 1996-11-07 1997-01-08 Eurand Int Novel pharmaceutical compositions
US5861291A (en) 1997-02-24 1999-01-19 Biozymes Inc. Method for producing pancreatin which contains low amounts of residual organic solvent and product thereof
JPH10295374A (ja) 1997-04-30 1998-11-10 Amano Pharmaceut Co Ltd 安定な酵素顆粒の製造法
DE19721467A1 (de) * 1997-05-22 1998-11-26 Basf Ag Verfahren zur Herstellung kleinteiliger Zubereitungen biologisch aktiver Stoffe
SE9702338D0 (sv) 1997-06-18 1997-06-18 Astra Ab An analytical method and industrial process including the same
ES2137862B1 (es) 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
JP3611456B2 (ja) 1997-09-30 2005-01-19 日研化学株式会社 テオフィリン徐放性錠剤
KR19990072826A (ko) 1998-02-26 1999-09-27 우재영 판크레아틴장용코팅과립의제조방법
US7201923B1 (en) 1998-03-23 2007-04-10 General Mills, Inc. Encapsulation of sensitive liquid components into a matrix to obtain discrete shelf-stable particles
US20010024660A1 (en) 1999-09-29 2001-09-27 Ismat Ullah Enteric coated pharmaceutical composition and method of manufacturing
US7122207B2 (en) 1998-05-22 2006-10-17 Bristol-Myers Squibb Company High drug load acid labile pharmaceutical composition
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
JP3071427B2 (ja) * 1998-10-09 2000-07-31 花王株式会社 酵素粒子
CN100444830C (zh) 1998-11-02 2008-12-24 伊兰公司，Plc 多颗粒改进释放组合物
EP1224273B1 (de) * 1999-10-01 2007-10-17 Novozymes A/S Enzymgranulat
US20010046493A1 (en) 2000-02-24 2001-11-29 Alex Margolin Lipase-containing composition and methods of use thereof
WO2001070047A1 (en) 2000-03-24 2001-09-27 Société des Produits Nestlé S.A. Nutritional composition comprising hydrolysed protein
AU2001244093A1 (en) 2000-04-03 2001-10-15 Novozymes A/S Enzyme tablets for cleaning improvement
IT1319655B1 (it) 2000-11-15 2003-10-23 Eurand Int Microsfere di enzimi pancreatici con elevata stabilita' e relativometodo di preparazione.
AR032392A1 (es) 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
AUPR272901A0 (en) 2001-01-25 2001-02-22 Gainful Plan Limited Method of preparing biological materials and preparations produced using same
DE60124895D1 (de) 2001-07-26 2007-01-11 Ethypharm Sa Umgehüllte Allylamine oder Benzylamine enthaltende Granulate, Verfahren zur Herstellung und in der Mundhöhle dispergierbare Tabletten enthaltend die umgehüllten Granulate
JP4187085B2 (ja) 2001-08-24 2008-11-26 三菱電機株式会社 車両用乗員保護装置
US20040197321A1 (en) 2002-03-19 2004-10-07 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
CN1156308C (zh) 2002-04-19 2004-07-07 北京世诺医药科技有限公司 多酶组合胶囊
US20040121010A1 (en) 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
AU2003288988A1 (en) 2002-11-29 2004-06-23 Freund Corporation Water-based shellac coating material, process for producing the same, coated food obtained with the coating material, process for producing the same, coated medicine, process for producing the same, glazing composition for oily snack, method of glazing, and glazed oily snack
CA2419572A1 (en) 2003-02-18 2004-08-18 Axcan Pharma Inc. High dosage protease formulation
US20040213847A1 (en) 2003-04-23 2004-10-28 Matharu Amol Singh Delayed release pharmaceutical compositions containing proton pump inhibitors
AU2004285558A1 (en) 2003-10-29 2005-05-12 Altus Pharmaceuticals Inc. Non-pancreatic proteases for controlling plasma cholecystokinin (CCK) concentration and for treating pain
US7670624B2 (en) 2004-01-29 2010-03-02 Astella Pharma Inc. Gastrointestinal-specific multiple drug release system
JP5032300B2 (ja) 2004-03-22 2012-09-26 アボット プロダクツ ゲゼルシャフト ミット ベシュレンクテル ハフツング 界面活性剤を含有している、リパーゼを含有する生成物の、とりわけパンクレアチンの経口医薬組成物
US20050281876A1 (en) 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US20060198838A1 (en) 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
SI1809320T1 (sl) 2004-10-14 2010-11-30 Cystic Fibrosis Foundation Therapeutics Inc Sestavki ki vsebujejo lipazo proteazo in amilazo za zdravljenje pankreasne insuficience
US20070025977A1 (en) 2005-07-21 2007-02-01 Mulberg Andrew E Method of treating steatorrhea in infants
KR101199196B1 (ko) 2005-07-25 2012-11-07 (주)다산메디켐 구형의 판크레아틴 과립의 제조방법
AU2006274835B2 (en) 2005-07-29 2012-05-24 Abbott Laboratories Gmbh Processes for the manufacture of sterilized pancreatin powder
JP5284092B2 (ja) 2005-08-15 2013-09-11 アボット ラボラトリーズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 腸溶コーティングに適したパンクレアチンマイクロペレットコア
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
DK1931316T4 (en) 2005-08-15 2017-05-15 Abbott Laboratories Gmbh Controlled-release pharmaceutical compositions for use in acid-labile drugs
WO2007053619A2 (en) 2005-11-01 2007-05-10 Bio-Cat, Inc. A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency
US20070141151A1 (en) 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
EP1967211A4 (de) 2005-12-28 2009-12-30 Takeda Pharmaceutical Verfahren zur herstellung eines sich in der mundhöhle zersetzenden feststoffpräparats
CN101370485A (zh) 2006-01-21 2009-02-18 艾博特股份有限两合公司 用于滥用药物给药的剂型和方法
BRPI0712087A2 (pt) 2006-05-26 2012-07-17 Nestec Ag métodos de uso e composições nutricionais de extrato de rouchi
WO2008017659A1 (en) 2006-08-07 2008-02-14 Novozymes A/S Enzyme granules for animal feed
KR100804096B1 (ko) 2006-08-31 2008-02-18 (주)아모레퍼시픽 고농도 계면활성제 계에서도 안정한 효소 캡슐 제제를포함하는 피부 세정용 조성물 및 그 제조방법
US20080199448A1 (en) 2007-02-16 2008-08-21 Ross Mairi R Enzyme composition for improving food digestion
US20090117180A1 (en) 2007-02-20 2009-05-07 Giovanni Ortenzi Stable digestive enzyme compositions
TWI421090B (zh) 2007-02-20 2014-01-01 Aptalis Pharma Ltd 穩定之消化酵素組合物
AU2008239737A1 (en) 2007-04-13 2008-10-23 Beth Israel Deaconess Medical Center, Inc. Novel nutritional food products for improved digestion and intestinal absorption
US10087493B2 (en) 2008-03-07 2018-10-02 Aptalis Pharma Canada Ulc Method for detecting infectious parvovirus in pharmaceutical preparations
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
CN101430279A (zh) 2008-10-27 2009-05-13 江南大学 荧光分光光度法筛选催化非水相体系转酯化反应用酶的方法
US8784884B2 (en) 2009-09-17 2014-07-22 Stephen Perrett Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency
US20110135728A1 (en) 2009-12-08 2011-06-09 Miller Jennifer L Gastric retentive pharmaceutical compositions for extended release of polypeptides
CN102883712A (zh) 2010-03-19 2013-01-16 加拿大阿普塔利斯制药公司 耐胃液酶药物组合物
GB201006178D0 (en) 2010-04-14 2010-06-02 Ayanda As Composition
UY33548A (es) 2010-08-06 2012-02-29 Eurand Pharmaceuticals Inc Formula nutricional predigerida
PT2621476E (pt) 2010-10-01 2014-10-16 Aptalis Pharma Ltd Formulações de pancrelipase de baixa potência com revestimento entérico
WO2012052853A2 (en) 2010-10-21 2012-04-26 Aptalis Pharma Limited Oral dosing device for administration of medication
CA2831213C (en) 2011-03-27 2016-05-17 Cellresin Technologies, Llc Cyclodextrin compositions, articles, and methods
RU2016119726A (ru) 2011-08-08 2018-11-02 Апталис Фарма Лтд. Способ проведения теста на растворение твердых композиций, содержащих пищеварительные ферменты
CA2905159C (en) 2013-03-15 2023-01-03 Aptalis Pharma Ltd. Composition containing digestive enzymes and nutrients suitable for enteral administration
CN105392496A (zh) 2013-07-22 2016-03-09 阿普塔利斯制药有限公司 高效的胰酶药物组合物
WO2015020943A2 (en) 2013-08-09 2015-02-12 Aptalis Pharma Ltd. Digestive enzyme composition suitable for enteral administration
AU2014346930A1 (en) 2013-11-05 2016-01-07 Aptalis Pharma Ltd. High potency pancreatin pharmaceutical compositions
JP2017519490A (ja) 2014-06-19 2017-07-20 アプタリス ファルマ リミテッド 膵臓抽出物からのウイルス汚染の除去方法

Also Published As

Publication number Publication date
ES2240559T3 (es) 2005-10-16
EP1335706B1 (de) 2005-04-13
CA2428837A1 (en) 2002-05-23
WO2002040045A2 (en) 2002-05-23
US9259393B2 (en) 2016-02-16
US20040101562A1 (en) 2004-05-27
ATE292959T1 (de) 2005-04-15
WO2002040045A3 (en) 2002-10-31
EP1335706A2 (de) 2003-08-20
AU2002224843A1 (en) 2002-05-27
US9884025B2 (en) 2018-02-06
US20160120815A1 (en) 2016-05-05
ITMI20002456A1 (it) 2002-05-15
JP4555981B2 (ja) 2010-10-06
JP2004513645A (ja) 2004-05-13
IT1319655B1 (it) 2003-10-23
KR20030060105A (ko) 2003-07-12
DE60110106T2 (de) 2006-03-02

Similar Documents

Publication Publication Date Title
DE60110106D1 (de) Verfahren zur herstellung von pankreasenzym enthaltende mikrosphären mit hoher stabilität
ATE315050T2 (de) Verfahren zur herstellung von mehrfach vernetzten hyaluronsäurederivaten
DE68925002D1 (de) Verfahren zur Herstellung von optisch-aktiven alpha-substituierten organischen Säuren und Mikroorganismen und Enzyme, die dafür verwendet werden.
WO2001070673A3 (en) CYCLIC β-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-$g(a)
EP1478322A4 (de) Beta-2'-OR 3'-HALONUCLEOSIDE
ATE407664T1 (de) Hydrogel zusammensetzungen, geeignet zur verzögerten freisetzung von makromolekülen sowie verfahren zur herstellung derselben.
DE50203302D1 (de) Verfahren zur herstellung von direkt tablettierbarem alpha-mannit
DE60042035D1 (de) Verfahren und zusammensetzungen zur herstellung von ophtalmischen linsen
DE69425820D1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
ATE204851T1 (de) Verfahren zur herstellung von retrovial protease hemmenden zwischenprodukten
DE60124289D1 (de) Verfahren zur herstellung von 21-hydroxy-6,19-oxidoprogesteron (21oh-6op)
ATE298747T1 (de) Verfahren zur herstellung von 5- hydroxybenzo(b)thiophen-3-carbonsäure
UA81649C2 (ru) Эфиры карбаминовой кислоты, которые имеют антихолинергическое действие
DE60034885D1 (de) Enzymlauge und verfahren zu deren herstellung, enzymzubereitung, proteasezubereitungen und proteaseproduzierendes bakterium
DE59712943D1 (de) Verfahren zur herstellung von (s)- oder (r)-3,3,3-trifluor-2-hydroxy-2-methylpropionsaüre
DE50009670D1 (de) Verfahren zur herstellung optisch aktiver amine
DE60213874D1 (de) Verfahren zur herstellung von protease hemmenden zwischenprodukten
ATE389010T1 (de) Verfahren zur herstellung von optisch aktiven pyridinethanol-derivaten
DE59106876D1 (de) Verfahren zur enzymatischen Herstellung optisch aktiver Cyanhydrine.
ATE417919T1 (de) Mikrobiologisches verfahren zur herstellung von amiden
ATE299851T1 (de) Verfahren zur herstellung von zwischenprodukten
ATE362543T1 (de) Verfahren zur herstellung von optisch aktiven beta-amino alkoholen
ATE248141T1 (de) Verfahren zur herstellung von (r) und (s)- aminocarnitin und deren derivative aus d- und l- aspargin säure
ATE540104T1 (de) Suspensionskultur von mykobakterien
ATE231486T1 (de) Optisch aktive 2-amino-tetraline, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen die diese enthalten und die nützlich sind zur vorbeugung und behandlung von septischem schock

Legal Events

Date Code Title Description
8363 Opposition against the patent
R081 Change of applicant/patentee

Ref document number: 1335706

Country of ref document: EP

Owner name: APTALIS PHARMA S.R.L., IT

Free format text: FORMER OWNER: EURAND INTERNATIONAL S.P.A., MAILAND/MILANO, IT

Effective date: 20110824

R082 Change of representative

Ref document number: 1335706

Country of ref document: EP

Representative=s name: NOTARBARTOLO & GERVASI GMBH, 80336 MUENCHEN, DE

R082 Change of representative

Ref document number: 1335706

Country of ref document: EP

Representative=s name: NOTARBARTOLO & GERVASI GMBH, 80336 MUENCHEN, DE